Qiagen (NYSE:QGEN) Announces Q3 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its third quarter 2026 earnings guidance on Friday. The company provided EPS guidance of 0.650-0.650 for the period, compared to the consensus estimate of 0.620. The company issued revenue guidance of $548.0 million, compared to the consensus revenue estimate of $534.1 million.

Qiagen Stock Performance

QGEN stock traded up $0.18 during trading on Friday, hitting $50.40. 2,376,403 shares of the company traded hands, compared to its average volume of 2,722,644. The stock’s 50-day simple moving average is $44.29 and its 200 day simple moving average is $40.58. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The company has a market cap of $10.39 billion, a PE ratio of 25.81, a P/E/G ratio of 4.98 and a beta of 0.61. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The business had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same quarter in the prior year, the firm posted $0.60 EPS. The business’s quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, equities analysts expect that Qiagen will post 2.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

QGEN has been the subject of several analyst reports. Robert W. Baird boosted their target price on shares of Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday. Citigroup restated a “neutral” rating and set a $45.00 price target (up from $38.00) on shares of Qiagen in a research report on Monday, August 10th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. Weiss Ratings raised shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 11th. Finally, UBS Group initiated coverage on shares of Qiagen in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Qiagen currently has a consensus rating of “Hold” and a consensus target price of $44.43.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Q3 guidance was raised above consensus. Qiagen issued adjusted EPS guidance of $0.65 and revenue guidance of $548 million, exceeding analyst expectations of $0.62 and $534.1 million, respectively. QIAGEN reports preliminary Q3 2026 results
• Positive Sentiment: Preliminary results confirmed the strong quarter. Preliminary third-quarter net sales reached $548 million and adjusted diluted EPS was $0.65, both ahead of expectations. Full results are scheduled for November 4, 2026. QIAGEN preliminary Q3 results
• Positive Sentiment: EQT’s all-cash takeover remains the primary catalyst. Qiagen agreed to be acquired for €46.50 per share in a transaction valued at approximately $12.1 billion, while reports indicate shareholder acceptance is unanimous and closing is nearing. The deal provides a defined cash value for shareholders. Qiagen to Be Acquired by EQT
• Positive Sentiment: Robert W. Baird upgraded its view. Baird raised its price target from $50 to $52 and assigned an “outperform” rating, implying modest additional upside. Baird analyst action
• Neutral Sentiment: Analyst sentiment is mixed. JPMorgan reaffirmed a “neutral” rating and reduced its price target from $55 to $52, suggesting the pending transaction may cap further gains. JPMorgan analyst action
• Neutral Sentiment: Call-option volume was approximately 94% above its typical level, indicating heightened trading interest but not necessarily a fundamental change in valuation.
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen is obtaining a fair price and adequately protecting shareholders. These reviews could create deal-related uncertainty, even though no wrongdoing has been established. Halper Sadeh Qiagen investigation

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.